Cargando…

Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study

OBJECTIVES: Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular events in statin-treated patients with first acute ischemic stroke...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lanjing, Liu, Lijun, Zhao, Yanhong, Chu, Min, Teng, Jijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671150/
https://www.ncbi.nlm.nih.gov/pubmed/36408516
http://dx.doi.org/10.3389/fneur.2022.1004264
_version_ 1784832479002099712
author Wang, Lanjing
Liu, Lijun
Zhao, Yanhong
Chu, Min
Teng, Jijun
author_facet Wang, Lanjing
Liu, Lijun
Zhao, Yanhong
Chu, Min
Teng, Jijun
author_sort Wang, Lanjing
collection PubMed
description OBJECTIVES: Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular events in statin-treated patients with first acute ischemic stroke (AIS). METHODS: Patients who were admitted to the hospital with first AIS from October 2018 to September 2020 were eligible for inclusion. Correlation between the change of Lp(a) levels and potential influencing factors was assessed by linear regression analysis. Cox proportional regression models were used to estimate the association between Lp(a) and recurrent vascular events including AIS, transient ischemic attack, myocardial infarction and coronary revascularization. RESULTS: In total, 303 patients, 69.6% males with mean age 64.26 ± 11.38 years, completed the follow-up. During the follow-up period, Lp(a) levels increased in 50.5% of statin-treated patients and the mean percent change of Lp(a) levels were 14.48% (95% CI 6.35–22.61%). Creatinine (β = 0.152, 95% CI 0.125–0.791, P = 0.007) and aspartate aminotransferase (AST) (β = 0.160, 95% CI 0.175–0.949, P = 0.005) were positively associated with the percent change of Lp(a) levels. During a median follow-up of 26 months, 66 (21.8%) patients had a recurrent vascular event. The median time period between AIS onset and vascular events recurrence was 9.5 months (IQR 2.0–16.3 months). The on-statin Lp(a) level ≥70 mg/dL (HR 2.539, 95% CI 1.076–5.990, P = 0.033) and the change of Lp(a) levels (HR 1.003, 95% CI 1.000–1.005, P = 0.033) were associated with the recurrent vascular events in statin-treated patients with first AIS. Furthermore, the on-statin Lp(a) levels ≥70 mg/dL (HR 3.612, 95% CI 1.018–12.815, P = 0.047) increased the risk of recurrent vascular events in patients with low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L. CONCLUSIONS: Lp(a) levels increased in half of statin-treated patients with first AIS. Creatinine and AST were positively associated with the percent change of Lp(a) levels. Lp(a) is a determinant of residual vascular risk and the change of Lp(a) is positively associated with the risk of recurrent vascular events in these patients.
format Online
Article
Text
id pubmed-9671150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96711502022-11-18 Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study Wang, Lanjing Liu, Lijun Zhao, Yanhong Chu, Min Teng, Jijun Front Neurol Neurology OBJECTIVES: Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular events in statin-treated patients with first acute ischemic stroke (AIS). METHODS: Patients who were admitted to the hospital with first AIS from October 2018 to September 2020 were eligible for inclusion. Correlation between the change of Lp(a) levels and potential influencing factors was assessed by linear regression analysis. Cox proportional regression models were used to estimate the association between Lp(a) and recurrent vascular events including AIS, transient ischemic attack, myocardial infarction and coronary revascularization. RESULTS: In total, 303 patients, 69.6% males with mean age 64.26 ± 11.38 years, completed the follow-up. During the follow-up period, Lp(a) levels increased in 50.5% of statin-treated patients and the mean percent change of Lp(a) levels were 14.48% (95% CI 6.35–22.61%). Creatinine (β = 0.152, 95% CI 0.125–0.791, P = 0.007) and aspartate aminotransferase (AST) (β = 0.160, 95% CI 0.175–0.949, P = 0.005) were positively associated with the percent change of Lp(a) levels. During a median follow-up of 26 months, 66 (21.8%) patients had a recurrent vascular event. The median time period between AIS onset and vascular events recurrence was 9.5 months (IQR 2.0–16.3 months). The on-statin Lp(a) level ≥70 mg/dL (HR 2.539, 95% CI 1.076–5.990, P = 0.033) and the change of Lp(a) levels (HR 1.003, 95% CI 1.000–1.005, P = 0.033) were associated with the recurrent vascular events in statin-treated patients with first AIS. Furthermore, the on-statin Lp(a) levels ≥70 mg/dL (HR 3.612, 95% CI 1.018–12.815, P = 0.047) increased the risk of recurrent vascular events in patients with low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L. CONCLUSIONS: Lp(a) levels increased in half of statin-treated patients with first AIS. Creatinine and AST were positively associated with the percent change of Lp(a) levels. Lp(a) is a determinant of residual vascular risk and the change of Lp(a) is positively associated with the risk of recurrent vascular events in these patients. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9671150/ /pubmed/36408516 http://dx.doi.org/10.3389/fneur.2022.1004264 Text en Copyright © 2022 Wang, Liu, Zhao, Chu and Teng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Wang, Lanjing
Liu, Lijun
Zhao, Yanhong
Chu, Min
Teng, Jijun
Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
title Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
title_full Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
title_fullStr Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
title_full_unstemmed Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
title_short Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study
title_sort lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: a prospective cohort study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671150/
https://www.ncbi.nlm.nih.gov/pubmed/36408516
http://dx.doi.org/10.3389/fneur.2022.1004264
work_keys_str_mv AT wanglanjing lipoproteinaandresidualvascularriskinstatintreatedpatientswithfirstacuteischemicstrokeaprospectivecohortstudy
AT liulijun lipoproteinaandresidualvascularriskinstatintreatedpatientswithfirstacuteischemicstrokeaprospectivecohortstudy
AT zhaoyanhong lipoproteinaandresidualvascularriskinstatintreatedpatientswithfirstacuteischemicstrokeaprospectivecohortstudy
AT chumin lipoproteinaandresidualvascularriskinstatintreatedpatientswithfirstacuteischemicstrokeaprospectivecohortstudy
AT tengjijun lipoproteinaandresidualvascularriskinstatintreatedpatientswithfirstacuteischemicstrokeaprospectivecohortstudy